Metropolitan Life Insurance CO I Teos Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Mar 30, 2023	SELL	$31.92 - $47.45 $149,353 - $222,018	-4,679 Reduced 77.42%	1,365 $43,000
Q1 2022 May 12, 2022	SELL	$31.92 - $47.45 $149,353 - $222,018	-4,679 Reduced 77.42%	1,365 $44,000
Q4 2021 Jun 21, 2023	BUY	$26.23 - $47.86 $122,730 - $223,936	4,679 Added 342.78%	6,044 $281,000
Q3 2021 Jun 21, 2023	BUY	$23.91 - $29.58 $111,874 - $138,404	4,679 Added 342.78%	6,044 $163,000
Q3 2021 Mar 30, 2023	SELL	$23.91 - $29.58 $14,585 - $18,043	-610 Reduced 9.17%	6,044 $163,000
Q3 2021 Nov 15, 2021	SELL	$23.91 - $29.58 $14,585 - $18,043	-610 Reduced 9.17%	6,044 $163,000
Q2 2021 Jun 21, 2023	BUY	$17.9 - $36.1 $94,673 - $190,932	5,289 Added 387.47%	6,654 $170,000
Q2 2021 Mar 30, 2023	BUY	$17.9 - $36.1 $14,463 - $29,168	808 Added 13.82%	6,654 $170,000
Q2 2021 Aug 16, 2021	BUY	$17.9 - $36.1 $118,999 - $239,992	6,648 Added 110800.0%	6,654 $171,000
Q1 2021 Jun 26, 2023	BUY	$30.86 - $44.2 $138,283 - $198,060	4,481 Added 328.28%	5,846 $200 Million
Q1 2021 Mar 30, 2023	BUY	$30.86 - $44.2 $75,267 - $107,803	2,439 Added 71.59%	5,846 $199,000
Q1 2021 May 14, 2021	SELL	$30.86 - $44.2 $104,954 - $150,324	-3,401 Reduced 99.82%	6 $200,000
Q4 2020 Jun 22, 2023	BUY	$21.59 - $33.95 $44,086 - $69,325	2,042 Added 149.6%	3,407 $115,000
Q3 2020 Jun 26, 2023	BUY	$17.57 - $32.92 $35,877 - $67,222	2,042 Added 149.6%	3,407 $84,000
Q3 2020 Mar 30, 2023	BUY	$17.57 - $32.92 $35,877 - $67,222	2,042 Added 149.6%	3,407 $84,000
Q3 2020 Nov 13, 2020	BUY	$17.57 - $32.92 $59,860 - $112,158	3,407 New	3,407 $84,000

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.